Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension
- 30 October 2023
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 24 (18) , 2101-2115
Abstract
Pulmonary arterial hypertension (PAH) is a severe, progressive pulmonary vasculopathy (Group 1 Pulmonary Hypertension (PH 1)) that complicates the course of many connective tissue diseases (CTD) and significantly impacts the quality and length of life of patients. Due to the various tissues that can be affected by CTD, detailed testing is required to differentiate true PAH from other types of pulmonary hypertension caused by CTD such as left heart disease (Group 2 PH), pulmonary parenchymal disease (Group 3 PH), and chronic thromboembolic pulmonary hypertension (Group 4 PH). CTD-associated PAH is most frequently seen in systemic sclerosis but can also be seen with systemic lupus erythematosus, mixed connective tissues disease, primary Sjogren's syndrome, and inflammatory myopathies. This review discusses the epidemiology of CTD-associated PAH, outlines the complex approach to obtaining a diagnosis, and finishes with an in-depth discussion on the current treatment paradigm with a focus on the pharmacological options available to patients. Focus is placed on the challenges faced in the treatment of CTD-associated PAH, in particular the decreased efficacy and poorer tolerance of pharmacological therapies and includes a discussion on the future investigational treatments that may alter the landscape of therapy. Despite significant advances over the past few decades with new medications and more aggressive treatment algorithms, patients with CTD-associated PAH are less likely to meet treatment targets and continue to have inferior survival compared to those with idiopathic PAH. This review concludes with our opinions on the current state of CTD-associated PAH, highlighting factors that lead to disparate outcomes compared to other forms of PAH, and a discussion on further improvements that may increase quality of life and survival for patients with CTD-associated PAH.Keywords
This publication has 118 references indexed in Scilit:
- The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort studyArthritis Research & Therapy, 2013
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionNew England Journal of Medicine, 2013
- Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategyAutoimmunity Reviews, 2013
- Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertensionEuropean Heart Journal, 2010
- Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosisClinical Rheumatology, 2010
- Tadalafil Therapy for Pulmonary Arterial HypertensionCirculation, 2009
- Long-term outcome with intravenous iloprost in pulmonary arterial hypertensionEuropean Respiratory Journal, 2009
- Changes in causes of death in systemic sclerosis, 1972–2002Annals of the Rheumatic Diseases, 2007
- Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensionsAnnals of the Rheumatic Diseases, 2006
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001